Enfermedad de Devic con respuesta favorable a rituximab: reporte de un caso

Danilo Fernando Orellana Cobos, Diana Lucila Berrezueta Córdova, Edison Damián Calle Samaniego, Carlos Eduardo Encalada García, Monica Elizabeth Pacurucu Jara

Producción científica: Contribución a una revistaArtículorevisión exhaustiva

Resumen

Devic’s disease, is also called neuromyelitis optica, it is a demyelinating autoimmune entity of the central nervous system, it is uncommon and it compromises the optic nerves and the spinal cord, causing loss of visual acuity and motor impairment. A clinical case of a 25-year-old woman with signs of sudden myelopathy and amaurosis is presented. It is fulfilling crite-ria for neuromyelitis optica. The treatment with methylprednisolone boluses started without any improvement, and Rituximab was applied with an early favorable response. Rituximab belongs to the group of anti-CD20 monoclo-nal antibodies, it was an important option in the absence of response to the first line of treatment.
Idioma originalEspañol
PublicaciónRevista de la Facultad de Ciencias Médicas de la Universidad de Cuenca
EstadoPublicada - 1 ene. 2019
Publicado de forma externa

Palabras clave

  • Informes de casos; Neuromielitis óptica; Rituximab

Citar esto